DOCSLIB.ORG

Advances in Immunology Associate Editors K

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in Immunology Associate Editors K VOLUME ONE HUNDRED AND SEVENTEEN ADVANCES IN IMMUNOLOGY ASSOCIATE EDITORS K. Frank Austen Harvard Medical School, Boston, Massachusetts, USA Tasuku Honjo Kyoto University, Kyoto, Japan Fritz Melchers University of Basel, Basel, Switzerland Jonathan W. Uhr University of Texas, Dallas, Texas, USA Emil R. Unanue Washington University, St. Louis, Missouri, USA VOLUME ONE HUNDRED AND SEVENTEEN ADVANCES IN IMMUNOLOGY Edited by FREDERICK W. ALT Howard Hughes Medical Institute, Boston, Massachusetts, USA AMSTERDAM • BOSTON • HEIDELBERG • LONDON NEW YORK • OXFORD • PARIS • SAN DIEGO SAN FRANCISCO • SINGAPORE • SYDNEY • TOKYO Academic Press is an imprint of Elsevier Academic Press is an imprint of Elsevier 525 B Street, Suite 1800, San Diego, CA 92101-4495, USA 225 Wyman Street, Waltham, MA 02451, USA The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK 32 Jamestown Road, London, NW1 7BY, UK Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands First edition 2013 Copyright © 2013 Elsevier Inc. All rights reserved No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher Permissions may be sought directly from Elsevier’s Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [email protected]. Alternatively you can submit your request online by visiting the Elsevier web site at http://elsevier.com/locate/permissions, and selecting Obtaining permission to use Elsevier material Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made ISBN: 978-0-12-410524-9 ISSN: 0065-2776 For information on all Academic Press publications visit our website at store.elsevier.com Printed and bound in USA 13 14 15 16 11 10 9 8 7 6 5 4 3 2 1 CONTENTS Contributors vii 1. Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression 1 Panagiotis Ntziachristos, Jasper Mullenders, Thomas Trimarchi, and Iannis Aifantis 1. Introduction 2 2. Aberrant DNA Methylation in Leukemia 6 3. Disruption of Histone-Modifying Complexes Polycomb and MLL in Leukemia 14 4. Other Epigenetic Writers, Erasers, and Readers 19 5. Novel Aspects and Technologies in Epigenetics: Implications for Leukemia 25 Acknowledgments 27 References 28 2. Translocations in Normal B Cells and Cancers: Insights from New Technical Approaches 39 Roberto Chiarle 1. Mechanistic Elements that Generate Chromosomal Translocations 40 2. Novel High-Throughput Methods to Study Chromosomal Translocations 50 3. New Findings on Translocation Formation Obtained by HTGTS and TC-Seq 52 4. Landscape of Translocations in Cancers 57 5. Perspectives 63 Acknowledgments 64 References 64 3. The Intestinal Microbiota in Chronic Liver Disease 73 Jorge Henao-Mejia, Eran Elinav, Christoph A. Thaiss, and Richard A. Flavell 1. Introduction 74 2. Role of the Intestinal Microbiota on Chronic Liver Diseases 75 3. Role of the Interactions Between the Innate Immune System and the Intestinal Microbiota on Chronic Liver Diseases 81 4. Probiotics and their Potential Role in Liver Disease Therapy 89 v vi Contents 5. Conclusions 90 References 91 4. Intracellular Pathogen Detection by RIG-I-Like Receptors 99 Evelyn Dixit and Jonathan C. Kagan 1. General Principles of the Antiviral Innate Immune Response 99 2. RLRs are RNA Sensors 101 3. RIG-I Activation and Receptor Proximal Signal Propagation 109 4. Regulatory Mechanisms of RIG-I Signaling 113 5. Conclusions and Future Directions 117 Acknowledgments 118 References 118 Index 127 Contents of Recent Volumes 133 CONTRIBUTORS Iannis Aifantis Howard Hughes Medical Institute; Department of Pathology, New York University School of Medicine; NYU Cancer Institute, New York University School of Medicine, and Helen and Martin S. Kimmel Stem Cell Center, New York University School of Medicine, New York, USA Roberto Chiarle Department of Pathology, Children’s Hospital Boston and Harvard Medical School, Boston, Massachusetts, USA, and Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy Evelyn Dixit Harvard Medical School and Division of Gastroenterology, Boston Children’s Hospital, Boston, Massachusetts, USA Eran Elinav Immunology Department, Weizmann Institute of Science, Rehovot, Israel Richard A. Flavell Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, and Howard Hughes Medical Institute, Chevy Chase, Maryland, USA Jorge Henao-Mejia Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA Jonathan C. Kagan Harvard Medical School and Division of Gastroenterology, Boston Children’s Hospital, Boston, Massachusetts, USA Jasper Mullenders Howard Hughes Medical Institute; Department of Pathology, New York University School of Medicine; NYU Cancer Institute, New York University School of Medicine, and Helen and Martin S. Kimmel Stem Cell Center, New York University School of Medicine, New York, USA Panagiotis Ntziachristos Howard Hughes Medical Institute; Department of Pathology, New York University School of Medicine; NYU Cancer Institute, New York University School of Medicine, and Helen and Martin S. Kimmel Stem Cell Center, New York University School of Medicine, New York, USA Christoph A. Thaiss Immunology Department, Weizmann Institute of Science, Rehovot, Israel Thomas Trimarchi Howard Hughes Medical Institute; Department of Pathology, New York University School of Medicine; NYU Cancer Institute, New York University School of Medicine, and Helen and Martin S. Kimmel Stem Cell Center, New York University School of Medicine, New York, USA vii Intentionally left as blank CHAPTER ONE Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression Panagiotis Ntziachristos*,†,‡,},1, Jasper Mullenders*,†,‡,},1, Thomas Trimarchi*,†,‡,}, Iannis Aifantis*,†,‡,},2 *Howard Hughes Medical Institute, New York, USA †Department of Pathology, New York University School of Medicine, New York, USA ‡NYU Cancer Institute, New York University School of Medicine, New York, USA }Helen and Martin S. Kimmel Stem Cell Center, New York University School of Medicine, New York, USA 1These authors contributed equally to this work 2Corresponding author: e-mail address: [email protected] Contents 1. Introduction 2 1.1 Leukemia as a heterogeneous and multifactorial disease 2 1.2 Epigenetic factors and their possible roles in leukemia 4 2. Aberrant DNA Methylation in Leukemia 6 2.1 The role of DNA methylation in hematopoietic malignancies 6 2.2 The role of DNMT3A in leukemia 7 2.3 The biology of TET proteins and their perturbations in leukemia 10 2.4 IDH1 and IDH2 oncometabolic proteins 12 3. Disruption of Histone-Modifying Complexes Polycomb and MLL in Leukemia 14 3.1 PRC2 in hematological neoplasms 14 3.2 Role of PRC1 in leukemia 17 3.3 MLL function 17 4. Other Epigenetic Writers, Erasers, and Readers 19 4.1 Arginine methyltransferases 19 4.2 Lysine demethylases (KDMs) 21 4.3 Histone demethylases inhibitors (KDMi) 22 4.4 Histone acetyl transferases 22 4.5 Histone deacetylases 23 4.6 Bromodomain-containing proteins 24 4.7 Plant homeodomain-containing proteins 24 4.8 Chromatin remodeling complexes 25 5. Novel Aspects and Technologies in Epigenetics: Implications for Leukemia 25 5.1 Combinatorial epigenetic marks 25 5.2 Novel aspects of regulation and epigenetic factors in cancer 26 Acknowledgments 27 References 28 Advances in Immunology, Volume 117 # 2013 Elsevier Inc. 1 ISSN 0065-2776 All rights reserved. http://dx.doi.org/10.1016/B978-0-12-410524-9.00001-3 2 Panagiotis Ntziachristos et al. Abstract Over the past decade, it has become clear that both genetics and epigenetics play pivotal roles in cancer onset and progression. The importance of epigenetic regulation in proper maintenance of cellular state is highlighted by the frequent mutation of chromatin mod- ulating factors across cancer subtypes. Identification of these mutations has created an interest in designing drugs that target enzymes involved in DNA methylation and post- translational modification of histones. In this review, we discuss recurrent genetic alter- ations to epigenetic modulators in both myeloid and lymphoid leukemias. Furthermore, we review how these perturbations contribute to leukemogenesis and impact disease outcome and treatment efficacy. Finally, we discuss how the recent advances in our understanding of chromatin biology may impact treatment of leukemia. 1. INTRODUCTION 1.1. Leukemia as a heterogeneous and multifactorial disease Hematopoietic malignancies are a broad category of diseases (Gilliland, 2001). Leukemia is one of the most aggressive among them and is charac- terized as the abnormal proliferation of immature cells of the hematopoietic system. Different types of leukemias can arise from lymphocytes (lympho- cytic leukemia), myeloid cells (myeloid leukemia), erythrocytes (erythro- cytic leukemia), and others in the bone marrow, lymph nodes, or spleen. Regardless of the cell type of origin, leukemia generally proceeds in either a chronic or an acute manner. Chronic disease consists of a long incubation period,
Load more

Recommended publications
  • Annual Conference Abstracts
    ANNUAL CONFERENCE 14-17 April 2014 Arena and Convention Centre, Liverpool ABSTRACTS SGM ANNUAL CONFERENCE APRIL 2014 ABSTRACTS (LI00Mo1210) – SGM Prize Medal Lecture (LI00Tu1210) – Marjory Stephenson Climate Change, Oceans, and Infectious Disease Prize Lecture Dr. Rita R. Colwell Understanding the basis of antibiotic resistance University of Maryland, College Park, MD, USA as a platform for early drug discovery During the mid-1980s, satellite sensors were developed to monitor Laura JV Piddock land and oceans for purposes of understanding climate, weather, School of Immunity & Infection and Institute of Microbiology and and vegetation distribution and seasonal variations. Subsequently Infection, University of Birmingham, UK inter-relationships of the environment and infectious diseases Antibiotic resistant bacteria are one of the greatest threats to human were investigated, both qualitatively and quantitatively, with health. Resistance can be mediated by numerous mechanisms documentation of the seasonality of diseases, notably malaria including mutations conferring changes to the genes encoding the and cholera by epidemiologists. The new research revealed a very target proteins as well as RND efflux pumps, which confer innate close interaction of the environment and many other infectious multi-drug resistance (MDR) to bacteria. The production of efflux diseases. With satellite sensors, these relationships were pumps can be increased, usually due to mutations in regulatory quantified and comparatively analyzed. More recent studies of genes, and this confers resistance to antibiotics that are often used epidemic diseases have provided models, both retrospective and to treat infections by Gram negative bacteria. RND MDR efflux prospective, for understanding and predicting disease epidemics, systems not only confer antibiotic resistance, but altered expression notably vector borne diseases.
    [Show full text]
  • Inflammasome Activation-Induced Hypercoagulopathy
    cells Review Inflammasome Activation-Induced Hypercoagulopathy: Impact on Cardiovascular Dysfunction Triggered in COVID-19 Patients Lealem Gedefaw, Sami Ullah, Polly H. M. Leung , Yin Cai, Shea-Ping Yip * and Chien-Ling Huang * Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong, China; [email protected] (L.G.); [email protected] (S.U.); [email protected] (P.H.M.L.); [email protected] (Y.C.) * Correspondence: [email protected] (S.-P.Y.); [email protected] (C.-L.H.) Abstract: Coronavirus disease 2019 (COVID-19) is the most devastating infectious disease in the 21st century with more than 2 million lives lost in less than a year. The activation of inflammasome in the host infected by SARS-CoV-2 is highly related to cytokine storm and hypercoagulopathy, which significantly contribute to the poor prognosis of COVID-19 patients. Even though many studies have shown the host defense mechanism induced by inflammasome against various viral infections, mechanistic interactions leading to downstream cellular responses and pathogenesis in COVID-19 remain unclear. The SARS-CoV-2 infection has been associated with numerous cardiovascular disor- ders including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. The inflammatory response triggered by the activation of NLRP3 inflammasome under certain car- diovascular conditions resulted in hyperinflammation or the modulation of angiotensin-converting enzyme 2 signaling pathways. Perturbations of several target cells and tissues have been described in inflammasome activation, including pneumocytes, macrophages, endothelial cells, and dendritic cells. Citation: Gedefaw, L.; Ullah, S.; Leung, P.H.M.; Cai, Y.; Yip, S.-P.; The interplay between inflammasome activation and hypercoagulopathy in COVID-19 patients is an Huang, C.-L.
    [Show full text]
  • DE-Kupl: Exhaustive Capture of Biological Variation in RNA-Seq Data Through K-Mer Decomposition
    Audoux et al. Genome Biology (2017) 18:243 DOI 10.1186/s13059-017-1372-2 METHOD Open Access DE-kupl: exhaustive capture of biological variation in RNA-seq data through k-mer decomposition Jérôme Audoux1, Nicolas Philippe2,3, Rayan Chikhi4, Mikaël Salson4, Mélina Gallopin5, Marc Gabriel5,6, Jérémy Le Coz5,EmilieDrouineau5, Thérèse Commes1,2 and Daniel Gautheret5,6* Abstract We introduce a k-mer-based computational protocol, DE-kupl, for capturing local RNA variation in a set of RNA-seq libraries, independently of a reference genome or transcriptome. DE-kupl extracts all k-mers with differential abundance directly from the raw data files. This enables the retrieval of virtually all variation present in an RNA-seq data set. This variation is subsequently assigned to biological events or entities such as differential long non-coding RNAs, splice and polyadenylation variants, introns, repeats, editing or mutation events, and exogenous RNA. Applying DE-kupl to human RNA-seq data sets identified multiple types of novel events, reproducibly across independent RNA-seq experiments. Background diversity is genomic variation. Polymorphism and struc- Successive generations of RNA-sequencing technologies tural variations within transcribed regions produce RNAs have bolstered the notion that organisms produce a highly with single-nucleotide variations (SNVs), tandem dupli- diverse and adaptable set of RNA molecules. Modern cations or deletions, transposon integrations, unstable transcript catalogs, such as GENCODE [1], now include microsatellites, or fusion events. These events are major hundreds of thousands of transcripts, reflecting pervasive sources of transcript variation that can strongly impact transcription and widespread alternative RNA processing. RNA processing, transport, and coding potential.
    [Show full text]
  • NLRP6 Induces Pyroptosis by Activation of Caspase-1 in Gingival
    JDRXXX10.1177/0022034518775036Journal of Dental ResearchNLRP6 Induces Pyroptosis 775036research-article2018 Research Reports: Biological Journal of Dental Research 2018, Vol. 97(12) 1391 –1398 © International & American Associations NLRP6 Induces Pyroptosis by Activation for Dental Research 2018 Article reuse guidelines: of Caspase-1 in Gingival Fibroblasts sagepub.com/journals-permissions DOI:https://doi.org/10.1177/0022034518775036 10.1177/0022034518775036 journals.sagepub.com/home/jdr W. Liu1* , J. Liu1*, W. Wang1, Y. Wang2,3, and X. Ouyang1 Abstract NLRP6, a member of the nucleotide-binding domain, leucine-rich repeat-containing (NLR) innate immune receptor family, has been reported to participate in inflammasome formation. Activation of inflammasome triggers a caspase-1–dependent programming cell death called pyroptosis. However, whether NLRP6 induces pyroptosis has not been investigated. In this study, we showed that NLRP6 overexpression activated caspase-1 and gasdermin-D and then induced pyroptosis of human gingival fibroblasts, resulting in release of proinflammatory mediators interleukin (IL)–1β and IL-18. Moreover, NLRP6 was highly expressed in gingival tissue of periodontitis compared with healthy controls. Porphyromonas gingivalis, which is a commensal bacterium and has periodontopathic potential, induced pyroptosis of gingival fibroblasts by activation of NLRP6. Together, we, for the first time, identified that NLRP6 could induce pyroptosis of gingival fibroblasts by activation of caspase-1 and may play a role in periodontitis. Keywords: periodontitis, pattern recognition receptors, cell death, Porphyromonas gingivalis, inflammasomes, flow cytometry Introduction have been demonstrated to participate in periodontitis (Huang et al. 2015; Chaves de Souza et al. 2016; Marchesan et al. Pyroptosis is a newly identified type of programmed cell death 2016).
    [Show full text]
  • Scholarly Commons NLRX1 Modulates Differentially NLRP3
    University of the Pacific Scholarly Commons Dugoni School of Dentistry Faculty Articles Arthur A. Dugoni School of Dentistry 10-1-2018 NLRX1 modulates differentially NLRP3 inflammasome activation and NF-κB signaling during Fusobacterium nucleatum infection Shu Chen Hung University of the Pacific Arthur A. Dugoni School of Dentistry Pei Rong Huang Chang Gung University Cassio Luiz Coutinho Almeida-Da-Silva University of the Pacific Arthur A. Dugoni School of Dentistry, [email protected] Kalina R. Atanasova University of Florida Ozlem Yilmaz Medical University of South Carolina See next page for additional authors Follow this and additional works at: https://scholarlycommons.pacific.edu/dugoni-facarticles Part of the Dentistry Commons Recommended Citation Hung, S., Huang, P., Almeida-Da-Silva, C. L., Atanasova, K. R., Yilmaz, O., & Ojcius, D. M. (2018). NLRX1 modulates differentially NLRP3 inflammasome activation and NF-κB signaling during Fusobacterium nucleatum infection. Microbes and Infection, 20(9-10), 615–625. DOI: 10.1016/j.micinf.2017.09.014 https://scholarlycommons.pacific.edu/dugoni-facarticles/705 This Article is brought to you for free and open access by the Arthur A. Dugoni School of Dentistry at Scholarly Commons. It has been accepted for inclusion in Dugoni School of Dentistry Faculty Articles by an authorized administrator of Scholarly Commons. For more information, please contact [email protected]. Authors Shu Chen Hung, Pei Rong Huang, Cassio Luiz Coutinho Almeida-Da-Silva, Kalina R. Atanasova, Ozlem Yilmaz, and David M. Ojcius This article is available at Scholarly Commons: https://scholarlycommons.pacific.edu/dugoni-facarticles/705 Version of Record: https://www.sciencedirect.com/science/article/pii/S1286457917301582 Manuscript_dd7f93413c97aff4865d54242a8b21e7 1 NLRX1 modulates differentially NLRP3 inflammasome activation 2 and NF-κB signaling during Fusobacterium nucleatum infection 3 4 5 Shu-Chen Hung 1, *, Pei-Rong Huang 2, Cássio Luiz Coutinho Almeida-da-Silva 1,3 , 6 Kalina R.
    [Show full text]
  • The Intestinal Parasite Cryptosporidium Is Controlled by an Enterocyte Intrinsic Inflammasome That Depends on NLRP6
    The intestinal parasite Cryptosporidium is controlled by an enterocyte intrinsic inflammasome that depends on NLRP6 Adam Saterialea,1, Jodi A. Gullicksruda, Julie B. Engilesa, Briana I. McLeoda, Emily M. Kuglera, Jorge Henao-Mejiab,c, Ting Zhoud, Aaron M. Ringd, Igor E. Brodskya, Christopher A. Huntera, and Boris Striepena,2 aDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104; bDepartment of Pathology and Laboratory Medicine, Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; cDivision of Protective Immunity, Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA 19104; and dDepartment of Immunology, Yale School of Medicine, Yale University, New Haven, CT 06519 Edited by Stephen M. Beverley, Washington University School of Medicine, St. Louis, MO, and approved December 1, 2020 (received for review April 24, 2020) The apicomplexan parasite Cryptosporidium infects the intestinal Murine infection with C. tyzzeri resembles human cryptospo- epithelium. While infection is widespread around the world, chil- ridiosis in location, pathology, and resolution and provides an dren in resource-poor settings suffer a disproportionate disease important tool to define the host and parasite factors that burden. Cryptosporidiosis is a leading cause of diarrheal disease, determine the outcome of infection and to identify the im- responsible for mortality and stunted growth in children. CD4 mune
    [Show full text]
  • Transcriptional Mechanisms of Resistance to Anti-PD-1 Therapy
    Author Manuscript Published OnlineFirst on February 13, 2017; DOI: 10.1158/1078-0432.CCR-17-0270 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Transcriptional mechanisms of resistance to anti-PD-1 therapy Maria L. Ascierto1, Alvin Makohon-Moore2, 11, Evan J. Lipson1, Janis M. Taube3,4, Tracee L. McMiller5, Alan E. Berger6, Jinshui Fan6, Genevieve J. Kaunitz3, Tricia R. Cottrell4, Zachary A. Kohutek7, Alexander Favorov8,10, Vladimir Makarov7,11, Nadeem Riaz7,11, Timothy A. Chan7,11, Leslie Cope8, Ralph H. Hruban4,9, Drew M. Pardoll1, Barry S. Taylor11,12,13, David B. Solit13, Christine A Iacobuzio-Donahue2,11, and Suzanne L. Topalian5 From the 1Departments of Oncology, 3Dermatology, 4Pathology, 5Surgery, 6The Lowe Family Genomics Core, 8Oncology Bioinformatics Core, and the 9 Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287; the 10Laboratory of System Biology and Computational Genetics, Vavilov Institute of General Genetics, Russian Academy of Sciences, 119991, Moscow, Russia; and 2Pathology, 7Radiation Oncology, 11Human Oncology and Pathogenesis Program, 12Department of Epidemiology and Biostatistics, and the 13Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York NY 10065. MLA, AM-M, EJL, and JMT contributed equally to this work Running title: Transcriptional mechanisms of resistance to anti-PD-1 Key Words: melanoma, cancer genetics, immunotherapy, anti-PD-1 Financial Support: This study was supported by the Melanoma Research Alliance (to SLT and CI-D), the Bloomberg~Kimmel Institute for Cancer Immunotherapy (to JMT, DMP, and SLT), the Barney Family Foundation (to SLT), Moving for Melanoma of Delaware (to SLT), the 1 Downloaded from clincancerres.aacrjournals.org on October 2, 2021.
    [Show full text]
  • Female Fellows of the Royal Society
    Female Fellows of the Royal Society Professor Jan Anderson FRS [1996] Professor Ruth Lynden-Bell FRS [2006] Professor Judith Armitage FRS [2013] Dr Mary Lyon FRS [1973] Professor Frances Ashcroft FMedSci FRS [1999] Professor Georgina Mace CBE FRS [2002] Professor Gillian Bates FMedSci FRS [2007] Professor Trudy Mackay FRS [2006] Professor Jean Beggs CBE FRS [1998] Professor Enid MacRobbie FRS [1991] Dame Jocelyn Bell Burnell DBE FRS [2003] Dr Philippa Marrack FMedSci FRS [1997] Dame Valerie Beral DBE FMedSci FRS [2006] Professor Dusa McDuff FRS [1994] Dr Mariann Bienz FMedSci FRS [2003] Professor Angela McLean FRS [2009] Professor Elizabeth Blackburn AC FRS [1992] Professor Anne Mills FMedSci FRS [2013] Professor Andrea Brand FMedSci FRS [2010] Professor Brenda Milner CC FRS [1979] Professor Eleanor Burbidge FRS [1964] Dr Anne O'Garra FMedSci FRS [2008] Professor Eleanor Campbell FRS [2010] Dame Bridget Ogilvie AC DBE FMedSci FRS [2003] Professor Doreen Cantrell FMedSci FRS [2011] Baroness Onora O'Neill * CBE FBA FMedSci FRS [2007] Professor Lorna Casselton CBE FRS [1999] Dame Linda Partridge DBE FMedSci FRS [1996] Professor Deborah Charlesworth FRS [2005] Dr Barbara Pearse FRS [1988] Professor Jennifer Clack FRS [2009] Professor Fiona Powrie FRS [2011] Professor Nicola Clayton FRS [2010] Professor Susan Rees FRS [2002] Professor Suzanne Cory AC FRS [1992] Professor Daniela Rhodes FRS [2007] Dame Kay Davies DBE FMedSci FRS [2003] Professor Elizabeth Robertson FRS [2003] Professor Caroline Dean OBE FRS [2004] Dame Carol Robinson DBE FMedSci
    [Show full text]
  • CD56+ T-Cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients
    CD56+ T-cells in Relation to Cytomegalovirus in Healthy Subjects and Kidney Transplant Patients Institute of Infection and Global Health Department of Clinical Infection, Microbiology and Immunology Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy by Mazen Mohammed Almehmadi December 2014 - 1 - Abstract Human T cells expressing CD56 are capable of tumour cell lysis following activation with interleukin-2 but their role in viral immunity has been less well studied. The work described in this thesis aimed to investigate CD56+ T-cells in relation to cytomegalovirus infection in healthy subjects and kidney transplant patients (KTPs). Proportions of CD56+ T cells were found to be highly significantly increased in healthy cytomegalovirus-seropositive (CMV+) compared to cytomegalovirus-seronegative (CMV-) subjects (8.38% ± 0.33 versus 3.29%± 0.33; P < 0.0001). In donor CMV-/recipient CMV- (D-/R-)- KTPs levels of CD56+ T cells were 1.9% ±0.35 versus 5.42% ±1.01 in D+/R- patients and 5.11% ±0.69 in R+ patients (P 0.0247 and < 0.0001 respectively). CD56+ T cells in both healthy CMV+ subjects and KTPs expressed markers of effector memory- RA T-cells (TEMRA) while in healthy CMV- subjects and D-/R- KTPs the phenotype was predominantly that of naïve T-cells. Other surface markers, CD8, CD4, CD58, CD57, CD94 and NKG2C were expressed by a significantly higher proportion of CD56+ T-cells in healthy CMV+ than CMV- subjects. Functional studies showed levels of pro-inflammatory cytokines IFN-γ and TNF-α, as well as granzyme B and CD107a were significantly higher in CD56+ T-cells from CMV+ than CMV- subjects following stimulation with CMV antigens.
    [Show full text]
  • Post-Transcriptional Inhibition of Luciferase Reporter Assays
    THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 34, pp. 28705–28716, August 17, 2012 © 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A. Post-transcriptional Inhibition of Luciferase Reporter Assays by the Nod-like Receptor Proteins NLRX1 and NLRC3* Received for publication, December 12, 2011, and in revised form, June 18, 2012 Published, JBC Papers in Press, June 20, 2012, DOI 10.1074/jbc.M111.333146 Arthur Ling‡1,2, Fraser Soares‡1,2, David O. Croitoru‡1,3, Ivan Tattoli‡§, Leticia A. M. Carneiro‡4, Michele Boniotto¶, Szilvia Benko‡5, Dana J. Philpott§, and Stephen E. Girardin‡6 From the Departments of ‡Laboratory Medicine and Pathobiology and §Immunology, University of Toronto, Toronto M6G 2T6, Canada, and the ¶Modulation of Innate Immune Response, INSERM U1012, Paris South University School of Medicine, 63, rue Gabriel Peri, 94276 Le Kremlin-Bicêtre, France Background: A number of Nod-like receptors (NLRs) have been shown to inhibit signal transduction pathways using luciferase reporter assays (LRAs). Results: Overexpression of NLRX1 and NLRC3 results in nonspecific post-transcriptional inhibition of LRAs. Conclusion: LRAs are not a reliable technique to assess the inhibitory function of NLRs. Downloaded from Significance: The inhibitory role of NLRs on specific signal transduction pathways needs to be reevaluated. Luciferase reporter assays (LRAs) are widely used to assess the Nod-like receptors (NLRs)7 represent an important class of activity of specific signal transduction pathways. Although pow- intracellular pattern recognition molecules (PRMs), which are erful, rapid and convenient, this technique can also generate implicated in the detection and response to microbe- and dan- www.jbc.org artifactual results, as revealed for instance in the case of high ger-associated molecular patterns (MAMPs and DAMPs), throughput screens of inhibitory molecules.
    [Show full text]
  • MUC4/MUC16/Muc20high Signature As a Marker of Poor Prognostic for Pancreatic, Colon and Stomach Cancers
    Jonckheere and Van Seuningen J Transl Med (2018) 16:259 https://doi.org/10.1186/s12967-018-1632-2 Journal of Translational Medicine RESEARCH Open Access Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large‑scale genomic databases: MUC4/MUC16/ MUC20 signature is associated with poor survival in human carcinomas Nicolas Jonckheere* and Isabelle Van Seuningen* Abstract Background: MUC4 is a membrane-bound mucin that promotes carcinogenetic progression and is often proposed as a promising biomarker for various carcinomas. In this manuscript, we analyzed large scale genomic datasets in order to evaluate MUC4 expression, identify genes that are correlated with MUC4 and propose new signatures as a prognostic marker of epithelial cancers. Methods: Using cBioportal or SurvExpress tools, we studied MUC4 expression in large-scale genomic public datasets of human cancer (the cancer genome atlas, TCGA) and cancer cell line encyclopedia (CCLE). Results: We identifed 187 co-expressed genes for which the expression is correlated with MUC4 expression. Gene ontology analysis showed they are notably involved in cell adhesion, cell–cell junctions, glycosylation and cell signal- ing. In addition, we showed that MUC4 expression is correlated with MUC16 and MUC20, two other membrane-bound mucins. We showed that MUC4 expression is associated with a poorer overall survival in TCGA cancers with diferent localizations including pancreatic cancer, bladder cancer, colon cancer, lung adenocarcinoma, lung squamous adeno- carcinoma, skin cancer and stomach cancer. We showed that the combination of MUC4, MUC16 and MUC20 signature is associated with statistically signifcant reduced overall survival and increased hazard ratio in pancreatic, colon and stomach cancer.
    [Show full text]
  • NOD-Like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy
    International Journal of Molecular Sciences Review NOD-like Receptors in the Eye: Uncovering Its Role in Diabetic Retinopathy Rayne R. Lim 1,2,3, Margaret E. Wieser 1, Rama R. Ganga 4, Veluchamy A. Barathi 5, Rajamani Lakshminarayanan 5 , Rajiv R. Mohan 1,2,3,6, Dean P. Hainsworth 6 and Shyam S. Chaurasia 1,2,3,* 1 Ocular Immunology and Angiogenesis Lab, University of Missouri, Columbia, MO 652011, USA; [email protected] (R.R.L.); [email protected] (M.E.W.); [email protected] (R.R.M.) 2 Department of Biomedical Sciences, University of Missouri, Columbia, MO 652011, USA 3 Ophthalmology, Harry S. Truman Memorial Veterans’ Hospital, Columbia, MO 652011, USA 4 Surgery, University of Missouri, Columbia, MO 652011, USA; [email protected] 5 Singapore Eye Research Institute, Singapore 169856, Singapore; [email protected] (V.A.B.); [email protected] (R.L.) 6 Mason Eye Institute, School of Medicine, University of Missouri, Columbia, MO 652011, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-573-882-3207 Received: 9 December 2019; Accepted: 27 January 2020; Published: 30 January 2020 Abstract: Diabetic retinopathy (DR) is an ocular complication of diabetes mellitus (DM). International Diabetic Federations (IDF) estimates up to 629 million people with DM by the year 2045 worldwide. Nearly 50% of DM patients will show evidence of diabetic-related eye problems. Therapeutic interventions for DR are limited and mostly involve surgical intervention at the late-stages of the disease. The lack of early-stage diagnostic tools and therapies, especially in DR, demands a better understanding of the biological processes involved in the etiology of disease progression.
    [Show full text]